InVivo Therapeutics Hldgs Corp (fka NVIVQ)

[XenaLives]

InVivo Therapeutics Announces Enrollment of First Two Patients into the INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury
May 29, 2019 08:00 AM Eastern Daylight Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first two patients have been enrolled into The INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury).

“We appreciate the investigators’ continued focus and willingness to support not only this trial, but also this underserved patient population. Ultimately, we hope to address a large unmet medical need for spinal cord injury patients”

Tweet this
“Having the first two patients enrolled into the INSPIRE 2.0 Study is a critical milestone for the company and for the spinal cord injury patient population, as there continues to be inadequate treatment options for these patients. With eight clinical sites now open for enrollment, we remain optimistic about continuing to execute on the INSPIRE 2.0 study and will provide updates when appropriate,” commented Richard Toselli, M.D., President and Chief Executive Officer of InVivo.

The INSPIRE 2.0 Study is a two-arm 20-patient (10 subjects in each study arm), randomized, controlled trial designed to provide clinical data that will supplement the existing clinical results from the company’s previous single-arm study (INSPIRE 1.0). The definition of study success for the INSPIRE 2.0 Study is that the difference in the proportion of subjects who demonstrate an improvement of at least one grade on ASIA Impairment Scale (AIS) assessment at the six-month primary endpoint follow-up visit between the Scaffold Arm and the Comparator Arm must be equal to or greater than 20%.

“We appreciate the investigators’ continued focus and willingness to support not only this trial, but also this underserved patient population. Ultimately, we hope to address a large unmet medical need for spinal cord injury patients,” concluded Dr. Toselli.

INSPIRE 1.0 Study Results

As previously announced by InVivo, 7 of 16 (44 percent) patients who reached the six-month primary endpoint visit in the INSPIRE 1.0 Study had an AIS conversion at 6 months, which is the primary endpoint of the INSPIRE 1.0 Study (defined as improvement in AIS grade from baseline for all evaluable patients at the six-month visit). Altogether, 19 patients were implanted with the Neuro-Spinal Scaffold in the INSPIRE 1.0 Study, which is officially closed. Three patients died within two weeks of implantation, each death deemed unrelated to the Neuro-Spinal Scaffold or implantation procedure by the respective site’s Principal Investigators. The Objective Performance Criterion (study success definition) for the INSPIRE 1.0 Study was a 25 percent AIS conversion rate based on the published conversion rates for thoracic spinal cord injury reported in the literature

https://www.businesswire.com/news/home/20190529005268/en/InVivo-Therapeutics-Announces-Enrollment-Patients-INSPIRE-2.0